Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Krzywinska, Ewelina ^a   Kantari Mimoun, Chahrazade ^a   Kerdiles, Yann ^b   Sobecki, Michal ^c   Isagawa, Takayuki ^d   Gotthardt, Dagmar ^e   Castells, Magali ^a   Haubold, Johannes ^f   Millien, Corinne ^a   Viel, Thomas ^a   Tavitian, Bertrand ^a   Takeda, Norihiko ^g   Fandrey, Joachim ^f   Vivier, Eric ^b   Sexl, Veronika ^c   Stockmann, Christian ^a,h  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

^d NAGASAKI UNIVERSITY   (Japan)

^e UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF TOKYO   (Japan)

^h UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; GRANZYME B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; OXYGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A;

BIOAVAILABILITY; CANCER; CELLS AND CELL COMPONENTS; INFILTRATION; INHIBITION; INHIBITOR; OXYGEN; TUMOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CANCER CELL; CANCER INFILTRATION; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR BLEEDING; TUMOR HYPOXIA; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; DEFICIENCY; EXPERIMENTAL NEOPLASM; GENETICS; HYPOXIA; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELLS, CULTURED; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KILLER CELLS, NATURAL; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85034602048     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01599-w     Document Type: Article

References (31)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285, 1182-1186 (1971)
2. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. &Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989)
3. Carmeliet, P. &Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011)
4. Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009)
5. Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found. Symp. 283, 106-120; discussion 121-105, 238-141 (2007)
6. Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818 (2008)
7. Stockmann, C., Schadendorf, D., Klose, R. &Helfrich, I. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front. Oncol. 4, 69 (2014)
8. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. &Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239-252 (2012)
9. Hanna, J. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12, 1065-1074 (2006)
10. Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865-873 (2008)
11. Schofield, C. J. &Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5, 343-354 (2004)
12. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399-408 (2012)
13. Nizet, V. &Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9, 609-617 (2009)
14. Ryan, H. E. et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015 (2000)
15. Eckelhart, E. et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117, 1565-1573 (2011)
16. Narni-Mancinelli, E. et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl. Acad. Sci. USA 108, 18324-18329 (2011)
17. Eberl, G., Colonna, M., Di Santo, J. P. &McKenzie, A. N. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 348, aaa6566 (2015)
18. Hayakawa, Y. &Smyth, M. J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517-1524 (2006)
19. Huntington, N. D., Vosshenrich, C. A. &Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703-714 (2007)
20. Sarkar, S. et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS ONE 8, e64835 (2013)
21. Gotthardt, D. et al. STAT5 Is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 6, 414-429 (2016)
22. Bertout, J. A., Patel, S. A. &Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008)
23. Olsson, A. K., Dimberg, A., Kreuger, J. &Claesson-Welsh, L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371 (2006)
24. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005)
25. Klose, R. et al. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat. Commun. 7, 12528 (2016)
26. Finisguerra, V. et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522, 349-353 (2015)
27. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D. &Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59, 1592-1598 (1999)
28. Velasquez, S. Y. et al. Short term hypoxia synergizes with interleukin 15 priming in driving glycolytic gene transcription and supports human natural killer cell activities. J. Biol. Chem. 291, 12960-12977 (2016)
29. Yao, L. et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93, 1612-1621 (1999)
30. Smyth, M. J., Crowe, N. Y. &Godfrey, D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463 (2001)
31. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000)